News
UNCY
5.21
+1.66%
0.09
Law Offices of Frank R. Cruz Encourages Unicycive Therapeutics, Inc. (UNCY) Shareholders To Inquire About Securities Fraud Class Action
Barchart · 1d ago
UNCY DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (NASDAQ: UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026
Barchart · 1d ago
Deadline Approaching: Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith
Barchart · 2d ago
Rosen Law Firm Urges Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Stockholders to Contact the Firm for Information About Their Rights
Barchart · 2d ago
Deadline Soon: Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
Barchart · 3d ago
Weekly Report: what happened at UNCY last week (0831-0904)?
Weekly Report · 3d ago
Unicycive Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – UNCY
Barchart · 3d ago
UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
Barchart · 5d ago
UNCY INVESTOR ALERT: Securities Class Action Filed Against Unicycive Therapeutics, Inc. – Investors Encouraged to Contact Kirby McInerney LLP
Barchart · 5d ago
Unicycive Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Barchart · 09/01 06:05
Weekly Report: what happened at UNCY last week (0824-0828)?
Weekly Report · 08/31 09:36
Weekly Report: what happened at UNCY last week (0817-0821)?
Weekly Report · 08/24 09:36
Unicycive Therapeutics Is Maintained at Speculative Buy by Benchmark
Dow Jones · 08/20 15:48
Benchmark Maintains Speculative Buy on Unicycive Therapeutics, Raises Price Target to $15
Benzinga · 08/20 15:38
Unicycive Therapeutics price target raised to $15 from $13 at Benchmark
TipRanks · 08/20 12:40
Analysts Are Bullish on Top Healthcare Stocks: Unicycive Therapeutics (UNCY), Praxis Precision Medicines (PRAX)
TipRanks · 08/20 11:30
Analyst Reaffirms Buy Rating on Unicycive, Maintaining 12-Month Price Target at $30 After FDA Procedural Setback
TipRanks · 08/18 17:05
Weekly Report: what happened at UNCY last week (0810-0814)?
Weekly Report · 08/17 09:37
Unicycive Therapeutics price target lowered to $20 from $22 at B. Riley
TipRanks · 08/17 07:39
Unicycive Therapeutics Is Maintained at Buy by Guggenheim
Dow Jones · 08/13 14:22
More
Webull provides a variety of real-time UNCY stock news. You can receive the latest news about Unicycive Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About UNCY
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.